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Copyright © 2008 JCBN Summary Urinary trypsin inhibitor (UTI), a serine protease inhibitor, has been widely used
in Japan as a drug for patients with acute inflammatory disorders such as disseminated
intravascular coagulation (DIC), shock, and pancreatitis. Recent in vitro studies have
demonstrated that serine protease inhibitors may have anti-inflammatory properties beyond
their inhibition of neutrophil elastase at the site of inflammation. However, the therapeutic
effects of UTI in vivo remain unclear. In this review, we introduce the roles of UTI in the
experimental systemic inflammatory response induced by both intraperitoneal and intra-
tracheal administration of lipopolysaccharide using UTI deficient and wild-type mice. Our
experiments suggest that UTI can protect against systemic inflammatory response and
subsequent organ injury induced by bacterial endotoxin, at least partly, through the inhibition
of proinflammatory cytokine and chemokine expression. UTI may therefore present an
attractive “rescue” therapeutic option for systemic inflammatory response syndromes such as
DIC, acute lung injury, and multiple organ dysfunction.
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Introduction
Bacterial infection can evoke shock, acute respiratory
failure, multiple organ failure, and disseminated intra-
vascular coagulation (DIC), resulting in a high mortality
rate. Lipopolysaccharide (LPS), a major component of the
outer membrane of gram-negative bacteria, initiates the
cascade of pathophysiological reactions called endotoxin
shock [1]. A number of mediators including lipid mediators,
cytokines, free radicals, complement fragments, coagulatory
factors, and proteases contribute to the pathogenesis of
endotoxin shock [2–6]. Among them, the products generated
from neutrophils are recognized to play important roles.
Activated neutrophils release various types of mediators
including proteases and oxygen radicals [7]. Protease-
antiprotease imbalance is involved in a variety of inflam-
matory diseases [8, 9]. Because neutrophil elastase exerts
the most injurious effects on many substrates (e.g. elastin,
type I–IV collagen, fibronectin, laminin, and proteogly-
cans), it can be a key mediator of tissue injury [10]. Indeed,
neutrophil elastase and cathepsin G-deficient mice have
shown resistance to lethal effects of LPS [11]. Further,
deficiency of secretory leukoprotease inhibitor also report-
edly caused higher mortality from endotoxin shock with
higher production of IL-6 and high mobility group-1 [12]. In
addition, Fitzal and co-workers have shown that blockade of
pancreatic proteases in the intestinal lumen ameliorates
systemic inflammation induced by intravenous administra-
tion of LPS [13]. Therefore, protease inhibitors may provide
a therapeutic option for inflammatory diseases/conditions.
UTI is a multivalent Kunitz-type serine protease inhibitorK. Inoue et al.
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that is found in human urine and blood. UTI is degenerated
from pre-α-/inter-α-trypsin inhibitors during inflammation
[14]. UTI reportedly inhibits neutrophil elastase activity in
vitro [15, 16] and trypsin activity in patients with pancreatitis
[17]. Although the therapeutic effects of UTI on circulatory
shock have been recognized, especially in Japan, the current
understanding of the target mechanisms/pathways remains
unsatisfactory. Tani and colleagues reported that UTI pro-
tects against septic shock induced by gram-negative bacteria
in vivo, but only estimated clinical signs such as cardiac
index, blood pressure, lactic acid, blood glucose, and blood
base values [18]. Another group showed that UTI protects
against hemorrhagic shock by preserving myocardial mito-
chondrial function [19]. However, these studies have a
critical limit in that the animals were treated with human-
derived UTI as a foreign protein; the direct effect of UTI on
inflammatory diseases including systemic inflammatory
response (SIRS) syndrome has never been examined in
knock-out mice.
Role of UTI in Systemic Inflammation Induced by
Intraperitoneal LPS Challenge
At first, the role of UTI in systemic inflammation using
mice deficient in UTI gene [20] was investigated. Both UTI
(−/−) and wild-type (C57/BL6: WT) mice were injected
intraperitoneally (i.p.) with vehicle or LPS at a dose of
1 mg/kg body weight. Phosphate-buffered saline (PBS) was
used as the vehicle for LPS. Evaluation of coagulatory and
fibrinolytic parameters and white blood cell (WBC) counts
at 72 h after i. p. challenge showed that fibrinogen levels
were significantly greater in LPS-challenged WT mice
(p<0.05) and LPS-challenged UTI (−/−) mice (p<0.01) than
in vehicle-challenged mice with the same genotypes. In the
presence of LPS, they were also significantly higher in UTI
(−/−) mice than in WT mice (p<0.05). WBC counts signifi-
cantly decreased after LPS challenge in UTI (−/−) mice
(p<0.01 versus other groups). LPS appeared to shorten PT
when compared to vehicle treatment in UTI (−/−) mice,
although this difference did not reach significance. In the
presence of LPS, prothrombin time was significantly shorter
in UTI (−/−) mice than in WT mice (p<0.05).
Histopathological changes in the lung, kidney, and liver of
both genotypes at 72 h after LPS challenge revealed severe
neutrophilic inflammation in UTI (−/−) lungs challenged
with LPS. In contrast, little neutrophilic infiltration was
found in LPS-treated WT mice. Vehicle treatment caused no
histopathological changes in either genotype. LPS challenge
induced neutrophilic infiltration around glomeruli and in the
interstinum of the kidneys of both genotypes. However, the
severity was more prominent in UTI (−/−) mice than in WT
mice in the presence of LPS. Vehicle treatment caused no
histopathological changes in either genotype. LPS caused
wide spread centrilobular vacuolation of hepatocytes and
neutrophilic infiltration in livers of both genotypes. In the
presence of LPS, there were no significant differences
between genotypes. Vehicle treatment caused no histo-
pathological changes in either genotype.
The protein expression of interleukin (IL)-1β, macrophage
inflammatory protein (MIP)-1α, MIP-2, macrophage
chemoattractant protein (MCP)-1, and keratinocyte
chemoattractant [21] in the lung, kidney, and liver 72 h after
LPS administration was evaluated. In the lung, LPS
challenge caused significant elevation of IL-1β, MIP-1α,
MIP-2, MCP-1, and keratinocyte-derived chemoattractant
(KC) levels in UTI (−/−) mice when compared to vehicle
challenge (p<0.01). In WT mice, LPS treatment signifi-
cantly enhanced the expression of IL-1β, MIP-1α, MIP-2,
MCP-1, and KC when compared to vehicle challenge. In the
presence of LPS, the lung expression of MCP-1 was
significantly greater in UTI (−/−) mice than in WT mice
(p<0.05). The results in the kidney and liver were similar to
those in the lung. These results suggest that UTI protects
against systemic inflammation induced by intraperitoneal
administration of LPS, at least partly, through the inhibition
of proinflamatory cytokine production/release [22].
Role of UTI in Acute Lung Inflammation Induced by
Intratracheal Challenge of LPS
In another series of studies, the role of UTI in another type
of SIRS, acute lung inflammation induced by pulmonary
exposure to LPS, was examined. In brief, UTI (−/−) and WT
mice were intratracheally treated with vehicle or LPS, and
sacrificed 24 h later. In both genotypes, LPS treatment
induced significant increases in the numbers of total cells
and neutrophils in bronchoalveolar lavage (BAL) fluid as
compared with vehicle treatment (p<0.01). LPS treatment
caused greater and significant increases in the numbers of
BAL total cells (p<0.05) and neutrophils (p<0.01) in UTI
(−/−) mice than in WT mice. Also, LPS treatment increased
the lung water content in both genotypes of mice (p<0.05)
when compared to vehicle treatment. UTI (−/−) mice,
however, showed a significantly greater increase in lung
water content when compared to WT mice (p<0.05)
following LPS treatment. Lung specimens stained with
hematoxylin and eosin 24 h after intratracheal instillation
showed that in the presence of LPS, WT mice showed
moderate infiltration of neutrophils. In UTI (−/−) mice, LPS
treatment led to a marked recruitment of neutrophils and
interstitial edema. Vehicle administration alone caused no
histological changes in either WT or UTI (−/−) mice. LPS
treatment induced significant elevation of the protein levels
of IL-1β, MIP-1α, MCP-1, and KC in lung homogenates
when compared to vehicle treatment in both genotypes
(p<0.01). In the presence of LPS, the local expression ofUTI Against Systemic Inflammatory Response
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MCP-1 and KC was significantly higher in UTI (−/−) mice
than in WT mice (p<0.05 for KC, p<0.01 for MCP-1).
Furthermore, immunohistochemical examination showed
that in the presence of LPS, immunoreactive 8-hydroxy-2'-
deoxyguanosine was detected in the lungs of both strains of
mice, but the staining was more prominent in UTI (−/−) mice
than in WT mice. On the other hand, immunoreactive nitro-
tyrosine was strongly detected only in UTI (−/−) mice
challenged with LPS. Quantitative gene expression analyses
of lung homogenates obtained 4 h after intratracheal
challenge showed that compared to vehicle treatment, LPS
treatment resulted in significant elevation of gene expression
for inducible nitric oxide synthase (iNOS) in both genotypes
of mice (p<0.05). In the presence of LPS, the local expres-
sion of iNOS was higher in UTI (−/−) mice than in WT mice.
These results suggest that UTI is also protective against
acute lung inflammation induced by intratracheal adminis-
tration of LPS, at least in part, via the local suppression of
proinflammatory cytokines [23] and antioxidation [24].
In conclusion, UTI protects against SIRS pathophysiology
and subsequent organ damage induced by LPS in mice, at
least partly, via the modulation of the proinflammatory
cytokine IL-1β, as well as chemokines such as MIP-2,
MCP-1, and KC (Fig. 1). These in vivo results provide direct
and novel molecular evidence for the “rescue” therapeutic
potential of UTI against systemic inflammatory responses
syndrome such as DIC, acute lung injury, and multiple organ
dysfunction syndrome.
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